<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   South American bartonellosis: Oroya fever and verruga peruana
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       South American bartonellosis: Oroya fever and verruga peruana
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        South American bartonellosis: Oroya fever and verruga peruana
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David H Spach, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ciro P Maguina, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eloy E Ordaya, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         South American bartonellosis, or Carrion's disease, is an infection caused by
         <em>
          Bartonella bacilliformis
         </em>
         , a pleomorphic gram-negative bacterium. This organism is transmitted to humans predominantly by female phlebotomine sand flies [
         <a href="#rid1">
          1,2
         </a>
         ]. The disease typically manifests as a biphasic illness, with an initial febrile phase, known as Oroya fever, followed by a secondary phase, characterized by the development of nodular skin lesions, known as verruga peruana. Variable clinical patterns associated with this infection have been observed, ranging from asymptomatic bacteremia to fulminant illness [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         Issues related to
         <em>
          B. bacilliformis
         </em>
         will be reviewed here; issues related to infection caused by other
         <em>
          Bartonella
         </em>
         species are discussed separately. (See related topics.)
        </p>
        <p class="headingAnchor" id="H14405285">
         <span class="h1">
          HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is evidence from pre-Columbian artifacts that the verrucous cutaneous form of the disease was present in South America at least 1000 years prior to the arrival of Europeans [
         <a href="#rid3">
          3
         </a>
         ]. During the Inca era, the disease was called "Sirki," which means "warts in blood." Subsequent descriptions of similar verrucous skin lesions emerged in the 16
         <sup>
          th
         </sup>
         century among Spanish conquistadors, and these lesions became known as verruga peruana [
         <a href="#rid2">
          2,4
         </a>
         ]. In 1871, a major outbreak of febrile hemolytic anemia occurred among workers constructing a railway line to the mining town of La Oroya near Lima, Peru; this outbreak resulted in the death of more than 4000 workers and was referred to as Oroya fever [
         <a href="#rid2">
          2
         </a>
         ]. Less than 15 years later, in 1885, Daniel Alcides Carrión, a Peruvian medical student, demonstrated that verruga peruana and Oroya fever are caused by the same organism; this discovery resulted from a heroic experiment in which when he injected himself with infectious skin lesion material from a patient with verruga peruana and soon thereafter developed a fatal infection with fever and severe hemolytic anemia [
         <a href="#rid2">
          2,4
         </a>
         ]. As a tribute to him, both manifestations of this disease were thereafter known as Carrion's disease [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6660551">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Carrion's disease is endemic to the "verruga zone," a region in the Andes Mountains of Peru, Colombia, and Ecuador, but new emerging areas have been described in these countries [
         <a href="#rid2">
          2,6,7
         </a>
         ]. Sporadic cases have been reported in Bolivia, Chile, and Guatemala [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         <em>
          B. bacilliformis
         </em>
         is transmitted by the bite of the female sand fly of the genus
         <em>
          Lutzomyia
         </em>
         spp. The vector typically lives 500 to 3200 meters (1600 to 10,500 feet) above sea level and feeds during the night, particularly at dusk [
         <a href="#rid1">
          1,9
         </a>
         ].
         <em>
          Lutzomyia verrucarum
         </em>
         is the most effective vector in Peru [
         <a href="#rid10">
          10
         </a>
         ]. Some outbreaks in nonendemic areas have been associated with other
         <em>
          Lutzomyia
         </em>
         species, such as
         <em>
          L. maranonensis
         </em>
         ,
         <em>
          L. robusta
         </em>
         , and
         <em>
          L. peruensis
         </em>
         , denoting the potential of the vector to adapt to other climates and spread the disease to other regions [
         <a href="#rid11">
          11-13
         </a>
         ].
         <em>
          Lutzomyia columbiana
         </em>
         has been proposed as a new potential vector for Carrion's disease in Colombia [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Other possible vectors have been described in areas where
         <em>
          Lutzomyia
         </em>
         spp are not commonly found.
         <em>
          B. bacilliformis
         </em>
         has been isolated by polymerase chain reaction in ticks (
         <em>
          Amblyomma
         </em>
         spp and
         <em>
          Rhipicephalus
         </em>
         spp) collected from tapirs and collared peccaries captured in the Peruvian Amazon [
         <a href="#rid14">
          14
         </a>
         ]. Humans are the principal hosts; no reservoir of
         <em>
          B. bacilliformis
         </em>
         has been identified in any domestic or wild animal.
        </p>
        <p>
         Oroya fever occurs most frequently among tourists and transient workers who are immunologically naïve to
         <em>
          B. bacilliformis
         </em>
         , whereas verruga peruana occurs most frequently among individuals living in the verruga zone. In one cohort study in an endemic region of Peru, the incidence in the general population was 12 cases per 100 person-years, with a breakdown of clinical manifestations as follows [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oroya fever (11 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Verruga peruana and a recent febrile illness suggestive of Oroya fever (37 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Verruga peruana without a recent febrile illness (32 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic infection (21 percent)
        </p>
        <p>
        </p>
        <p>
         Infection occurred most frequently among children &lt;5 years of age (38 cases per 100 person-years), and there was a linear decrease in incidence with increasing age. Clustering of cases was also observed; 70 percent of cases occurred in 18 percent of households.
        </p>
        <p>
         Underreporting can occur in the setting of mild infection. One series of 11 patients with chronic verrucous skin lesions was described in a coastal, lowland region of Ecuador [
         <a href="#rid15">
          15
         </a>
         ]. A serologic study of more than 200 individuals in the surrounding region noted 21 percent seropositivity among contacts of index cases. Likewise, a study done among healthy children in six rural communities in the highlands of Ecuador showed a seroprevalence of 28 percent [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Vertical transmission of
         <em>
          B. bacilliformis
         </em>
         to a newborn whose mother had a febrile illness in the third trimester of pregnancy has been described [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Climate change has been associated with increases in the incidence of Carrion's disease in Peru, as occurred during the El Niño events of 1986 to 1988 and 1997 to 1998 [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14405321">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          B. bacilliformis
         </em>
         was the first
         <em>
          Bartonella
         </em>
         organism identified as a human pathogen. It is an intracellular, pleomorphic, gram-negative bacterium that is the recognized causative organism of Oroya fever and verruga peruana.
        </p>
        <p>
         It is possible that some illnesses previously attributed to
         <em>
          B. bacilliformis
         </em>
         are due to a subsequently recognized
         <em>
          Bartonella
         </em>
         species,
         <em>
          Bartonella rochalimae
         </em>
         ; this organism was isolated from an American tourist who presented with fever, splenomegaly, anemia, and a history of insect bites after a trip to Peru that included travel to a region in which
         <em>
          B. bacilliformis
         </em>
         is endemic [
         <a href="#rid19">
          19
         </a>
         ]. Studies performed in endemic and nonendemic areas for
         <em>
          B. bacilliformis
         </em>
         have demonstrated
         <em>
          B. rochalimae
         </em>
         infection in asymptomatic dogs as well as in fleas from cats and guinea pigs; these findings support the potential zoonotic transmission of this pathogen [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         Another
         <em>
          Bartonella
         </em>
         species,
         <em>
          Bartonella ancashensis,
         </em>
         was identified in 2003 during an antibiotic treatment trial of patients with verruga peruana; two patients were infected with a
         <em>
          Bartonella
         </em>
         species distinct from any known
         <em>
          Bartonella
         </em>
         species, and molecular analysis identified a new species that is phylogenetically similar to
         <em>
          B. bacilliformis
         </em>
         [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14405361">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          B. bacilliformis
         </em>
         produces virulence factors, including adhesin, flagellin, and
         <a class="drug drug_general" data-topicid="8970" href="/z/d/drug information/8970.html" rel="external">
          hemin
         </a>
         , that alter the immune system and allow the organism to evade the host immune response [
         <a href="#rid25">
          25
         </a>
         ]. In addition, these virulence factors facilitate the organism's invasion of erythrocytes (causing intraerythrocytic replication and hemolysis) and replication within endothelial cells (promoting proliferation and angiogenesis) [
         <a href="#rid25">
          25
         </a>
         ]. In the acute phase, the organism causes a substantial increase in interleukin-10 secretion by erythrocytes, which attenuates cytokine production and suppresses the function of certain immune cells, including T helper cells, macrophages, and dendritic cells [
         <a href="#rid26">
          26,27
         </a>
         ]. This perturbation in host immune function favors persistent B
         <em>
          . bacilliformis
         </em>
         infection and creates an immune state that is more vulnerable to secondary infection with bacterial pathogens. During the chronic form, there are high levels of interferon-gamma and interleukin-4 [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         It was previously believed that
         <em>
          B. bacilliformis
         </em>
         was the only
         <em>
          Bartonella
         </em>
         with multiple unipolar flagella; this characteristic provides a unique mechanism to enter erythrocytes. Subsequently, multiple unipolar flagella have been observed in other
         <em>
          Bartonella
         </em>
         species, including
         <em>
          B. rochalimae
         </em>
         ,
         <em>
          B. schoenbuchii
         </em>
         , and
         <em>
          B. clarridgeiae
         </em>
         [
         <a href="#rid19">
          19,29,30
         </a>
         ]. Other organisms lacking these flagella are capable of entering red blood cells via other mechanisms.
        </p>
        <p>
         In the chronic form of the disease, the bacterium invades endothelial cells, forms Rocha-Lima inclusion bodies, and causes overproduction of epidermal growth factor (EGF); the abundant production of EGF stimulates endothelial proliferation and angiogenesis, producing hypervascular nodules. Similar events have been described in the setting of infection due to other
         <em>
          Bartonella
         </em>
         species that cause bacillary angiomatosis [
         <a href="#rid31">
          31,32
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5512.html" rel="external">
          "Bartonella infections in people with HIV", section on 'Bacillary angiomatosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection with
         <em>
          B. bacilliformis
         </em>
         causes an acute febrile illness, Oroya fever, and a secondary phase with chronic cutaneous manifestations, verruga peruana [
         <a href="#rid33">
          33,34
         </a>
         ]. Other clinical presentations may also occur, including asymptomatic or chronic bacteremia, verruga peruana without Oroya fever, or recurrent verrucous illness; serologic surveys indicate that as many as 56 percent of seropositive individuals have asymptomatic infection [
         <a href="#rid35">
          35
         </a>
         ]. In addition, many patients who develop verruga peruana lesions do not recall a history of febrile illness in the preceding three months [
         <a href="#rid9">
          9,34
         </a>
         ]. The incubation period of South American bartonellosis is 1 to 30 weeks (mean 8 weeks) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Acute phase (Oroya fever)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute, or hematic, phase generally begins with an insidious onset of mild fever, headache, anorexia, and malaise [
         <a href="#rid33">
          33
         </a>
         ]. In one review that included 145 patients with bartonellosis, the most common clinical features were fever, pallor, malaise, painless hepatomegaly, and lymphadenopathy [
         <a href="#rid34">
          34
         </a>
         ]. Anemia develops due to parasitic infection of red blood cells and cells of the reticuloendothelial system, with subsequent clearance of parasitized cells from circulation [
         <a href="#rid36">
          36
         </a>
         ]. The acute phase lasts two to four weeks, and the majority of patients who receive treatment recover; progression to the eruptive phase occurs after weeks or months in less than 5 percent of cases.
        </p>
        <p>
         In the absence of antimicrobial therapy, mortality can reach 90 percent; when treatment is started early, mortality is generally less than 10 percent [
         <a href="#rid34">
          34
         </a>
         ]. Factors associated with poor prognosis include the presence of anasarca, petechiae, and altered mental status [
         <a href="#rid34">
          34
         </a>
         ]. Other risk factors associated with increased mortality include age &gt;45 years, history of alcohol use, and presentation with shock, pulmonary edema, pericarditis, seizures, or coma [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Acute phase secondary complications are common, as discussed in the following section.
        </p>
        <p class="headingAnchor" id="H6660793">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infectious and/or noninfectious complications occur in up to 70 percent of patients with Oroya fever.
        </p>
        <p>
         Infectious complications include secondary infection with
         <em>
          Salmonella
         </em>
         (
         <em>
          typhi
         </em>
         and non-
         <em>
          typhi
         </em>
         ),
         <em>
          Shigella dysenteriae
         </em>
         ,
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Klebsiella
         </em>
         spp,
         <em>
          Enterobacter
         </em>
         spp,
         <em>
          Candida
         </em>
         spp, toxoplasmosis reactivation, disseminated histoplasmosis,
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia, leptospirosis, and malaria due to
         <em>
          Plasmodium vivax
         </em>
         [
         <a href="#rid34">
          34,38-40
         </a>
         ]. Apart from hemolytic anemia associated with
         <em>
          Bartonella
         </em>
         described earlier, other hematological syndromes include disseminated intravascular coagulation, autoimmune hemolytic anemia, hemophagocytic syndrome, and thrombocytic purpura [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Noninfectious complications include anasarca, neurologic manifestations, ocular compromise, and cardiovascular complications [
         <a href="#rid34">
          34
         </a>
         ]. In one study that included 68 patients with Oroya fever in Peru, cardiovascular complications were observed in 53 percent of cases; the investigators reported a range of cardiovascular complications [
         <a href="#rid42">
          42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heart failure – 91 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pericardial effusion – 44 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary edema – 36 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiogenic shock – 17 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac tamponade – 11 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myocarditis – 11 percent
        </p>
        <p>
        </p>
        <p>
         In addition,
         <em>
          B. bacilliformis
         </em>
         has been reported as the etiology of acute endocarditis in a child with congenital coronary artery-to-right ventricular fistula and in an adult whose clinical course was complicated by the development of systemic vasculitis [
         <a href="#rid38">
          38,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Eruptive phase (verruga peruana)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The eruptive, or verruga, phase occurs after organisms invade capillary endothelial cells and induce cellular proliferation, producing hemangioma-like nodules in the skin and mucous membranes [
         <a href="#rid33">
          33
         </a>
         ]. Verruga peruana can appear two to eight weeks after the patient has apparently recovered from Oroya fever [
         <a href="#rid3">
          3,44
         </a>
         ]. However, most patients with verruga peruana do not have an antecedent history of febrile illness.
        </p>
        <p>
         There are three major types of skin lesions: miliary, nodular, and mular [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Miliary lesions are small (less than 3 mm), round, soft, reddish pinpoint papules clustered in crops that are confined to the papillary dermis  (
         <a class="graphic graphic_picture graphicRef66284" href="/z/d/graphic/66284.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid36">
          36,44
         </a>
         ]. Untreated, these lesions can progress to the nodular phase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mular lesions are nodular lesions that evolve into larger (&gt;5 mm) lesions  (
         <a class="graphic graphic_picture graphicRef76799" href="/z/d/graphic/76799.html" rel="external">
          picture 2
         </a>
         ). These lesions are highly vascular, bulbous, tend to bleed easily, and can ulcerate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nodular lesions are nontender wart-like lesions that may become pedunculated  (
         <a class="graphic graphic_picture graphicRef60673" href="/z/d/graphic/60673.html" rel="external">
          picture 3
         </a>
         ). Some subcutaneous lesions become apparent with a purplish color on the skin surface as they push upward, thinning the overlying skin.
        </p>
        <p>
        </p>
        <p>
         Lesions usually develop on the skin but can also involve mucous membranes. Lesions of more than one type may occur simultaneously in a given patient [
         <a href="#rid44">
          44
         </a>
         ]. In the absence of antimicrobial therapy, lesions may persist for months or years. Patients with verruga peruana often have concomitant systemic symptoms like fever, malaise, or osteoarticular pain [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         As lesions regress, they become more pale because of diminished vascularization. There may be some residual hyperpigmentation, but scarring does not usually occur. Recurrence of verrucous lesions has also been described. Mortality in the eruptive phase is very low [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         The verruga lesions are formed by proliferation of capillaries and endothelial cell hyperplasia and are similar to those seen in cutaneous bacillary angiomatosis and Kaposi's sarcoma. (See
         <a class="medical medical_review" href="/z/d/html/5512.html" rel="external">
          "Bartonella infections in people with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8034.html" rel="external">
          "AIDS-related Kaposi sarcoma: Staging and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16718024">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of Oroya fever is established by blood culture or by identification of
         <em>
          B. bacilliformis
         </em>
         organisms on a Giemsa-stained blood smear  (
         <a class="graphic graphic_picture graphicRef58621" href="/z/d/graphic/58621.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid44">
          44
         </a>
         ]. More than 70 percent of patients with acute Oroya fever have a positive blood culture for
         <em>
          B. bacilliformis
         </em>
         ; there may be a delay of more than 14 days for the organism to grow in culture.
         <em>
          B. bacilliformis
         </em>
         is fastidious and requires Columbia agar, an enriched blood medium, for growth, which occurs most readily at 25 to 28°C; other
         <em>
          Bartonella
         </em>
         spp grow readily at 37°C [
         <a href="#rid46">
          46
         </a>
         ]. Routine blood cultures are useful to evaluate for the presence of secondary bacteremia. The reliability of microscopy depends on the skill of the laboratory technician and may be associated with misdiagnosis [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         The diagnosis of verruga peruana is generally based on characteristic clinical features, with or without skin biopsy [
         <a href="#rid34">
          34
         </a>
         ]. Studies have reported positive blood cultures for
         <em>
          B. bacilliformis
         </em>
         in 13 to 47 percent of patients with verruga peruana, but the clinical significance of bacteremia at this stage is unknown since many of these represent asymptomatic or transient bacteremia [
         <a href="#rid34">
          34,48
         </a>
         ].
        </p>
        <p>
         The histologic findings consist of a highly dense proliferation of small- and large-sized blood vessels [
         <a href="#rid49">
          49
         </a>
         ]. Neutrophils and endothelial cells predominate in the dermis; histiocytes, plasma cells, lymphocytes, and mast cells are also variably present. Hyperkeratosis, parakeratosis, and mild acanthosis are observed in the epidermis. In some cases, Giemsa staining of a biopsy sample demonstrates characteristic cytoplasmic inclusions, referred to as Rocha-Lima inclusions [
         <a href="#rid49">
          49
         </a>
         ]. In addition, electron microscopy allows visualization of the
         <em>
          B. bacilliformis
         </em>
         organism [
         <a href="#rid49">
          49
         </a>
         ]. Phagocytized
         <em>
          B. bacilliformis
         </em>
         may be observed within neutrophils, histiocytes, and/or endothelial cells [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         Serologic tests for
         <em>
          B. bacilliformis
         </em>
         infection have been developed [
         <a href="#rid51">
          51
         </a>
         ], including an immunoblot test that uses a sonicate of whole
         <em>
          B. bacilliformis
         </em>
         as an antigen [
         <a href="#rid52">
          52
         </a>
         ], and an indirect fluorescence antibody test [
         <a href="#rid48">
          48
         </a>
         ]. These tests have been useful in epidemiologic studies [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Excellent results with polymerase chain reaction (PCR) techniques for diagnosing
         <em>
          B
         </em>
         .
         <em>
          bacilliformis
         </em>
         on blood samples from patients with clinically diagnosed Oroya fever have been described [
         <a href="#rid53">
          53
         </a>
         ]. Among the different approaches,
         <em>
          Bartonella
         </em>
         -specific 16S rRNA PCR presents the lowest detection limit (5 colony-forming units/mcL) in blood samples and dried blood spots, improving the detection of patients with low-level bacteremia [
         <a href="#rid54">
          54
         </a>
         ]. However, its high cost and the lack of molecular laboratories in endemic areas limits its use [
         <a href="#rid53">
          53,55
         </a>
         ]. Loop-mediated isothermal amplification, a nucleic acid amplification method, demonstrates similar sensitivity to PCR but requires less specialized equipment, enabling use in some endemic areas [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         South American bartonellosis may be confused with other illnesses that cause fever or cutaneous lesions. Oroya fever can mimic other infectious and tropical diseases  (
         <a class="graphic graphic_table graphicRef93381" href="/z/d/graphic/93381.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Zika and Chikungunya fever are arboviruses in South America that cause acute febrile illness in areas where Oroya fever has been described. (See
         <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">
          "Zika virus infection: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3024.html" rel="external">
          "Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malaria and dengue share some common clinical features and similar endemic patterns with Oroya fever. (See
         <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">
          "Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">
          "Dengue virus infection: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oroya fever may mimic infection with
         <em>
          Salmonella typhi
         </em>
         in areas of the tropics where typhoid fever is common, particularly in patients with prominent gastrointestinal complaints. In addition, typhi and non-typhi
         <em>
          Salmonella
         </em>
         may cause secondary infection in patients with Oroya fever. (See
         <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">
          "Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Viral hepatitis constitutes an important differential diagnosis in the highlands and the Amazon basin, where prevalence of both conditions is high.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some clinical features of Oroya fever overlap with those of leptospirosis. (See
         <a class="medical medical_review" href="/z/d/html/5527.html" rel="external">
          "Leptospirosis: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bartonellosis may have features that overlap with hematologic malignancy such as acute leukemia. (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Verruga peruana may need to be differentiated from other skin conditions, including  (
         <a class="graphic graphic_table graphicRef93381" href="/z/d/graphic/93381.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacillary angiomatosis – Bacillary angiomatosis occurs most often in patients with HIV infection or other form of immunosuppression. (See
         <a class="medical medical_review" href="/z/d/html/5512.html" rel="external">
          "Bartonella infections in people with HIV", section on 'Bacillary angiomatosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Yaws – Yaws causes papules with subsequent ulceration. Clinical diagnosis is generally straightforward in endemic areas; confirmation requires serology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pyogenic granuloma – Pyogenic granuloma is a benign vascular tumor of the skin or mucous membrane. (See
         <a class="medical medical_review" href="/z/d/html/13736.html" rel="external">
          "Pyogenic granuloma (lobular capillary hemangioma)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angioma – An angioma is a capillary proliferation on the skin. (See
         <a class="medical medical_review" href="/z/d/html/5573.html" rel="external">
          "Overview of benign lesions of the skin", section on 'Cherry angioma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous lymphoma – Cutaneous lymphomas are a heterogeneous group of T cell and B cell neoplasms that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/109157.html" rel="external">
          "Classification of primary cutaneous lymphomas"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Capillary malformation – Capillary malformation is a vascular malformation with nodular features that is present at birth. (See
         <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">
          "Capillary malformations (port wine birthmarks) and associated syndromes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kaposi sarcoma – Kaposi sarcoma is an angioproliferative disorder due to infection with human herpesvirus 8. (See
         <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">
          "Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tuberculosis and atypical mycobacterial infection – Rapidly growing mycobacteria can cause cutaneous infection. (See
         <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">
          "Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mpox – Mpox is an emerging disease caused by monkeypox virus; it can manifest as a painful rash involving the face and extremities, similar to verruga peruana. (See
         <a class="medical medical_review" href="/z/d/html/139254.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of mpox (monkeypox)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt initiation of appropriate antimicrobial therapy is essential for patients with known or suspected
         <em>
          Bartonellosis
         </em>
         infection  (
         <a class="graphic graphic_table graphicRef77298" href="/z/d/graphic/77298.html" rel="external">
          table 2
         </a>
         ). The optimal approach to treatment is uncertain; clinical practice is based on small case series.
        </p>
        <p>
         In vitro susceptibility testing for
         <em>
          Bartonella
         </em>
         species is difficult because the organism is fastidious; primary isolation requires up to four weeks of incubation on blood agar plates [
         <a href="#rid57">
          57
         </a>
         ]. Multiple antimicrobial agents are active against
         <em>
          B. bacilliformis
         </em>
         in vitro, including
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         , fluoroquinolones, penicillins, cephalosporins,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         .
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , aminoglycosides, and
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         are not considered good treatment options for this organism since relatively high doses are required to inhibit bacterial growth [
         <a href="#rid1">
          1,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Oroya fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         For treatment of uncomplicated Oroya fever in nonpregnant adults, we favor
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ; data for this approach are limited and largely based on observational data and clinical experience [
         <a href="#rid57">
          57
         </a>
         ]. There are no well-designed clinical trials that have evaluated the possible resistance of
         <em>
          B. bacilliformis
         </em>
         to ciprofloxacin, but limited in vitro data has suggested intrinsic resistance and reduced susceptibility to nalidixic acid and ciprofloxacin among some isolates [
         <a href="#rid58">
          58-60
         </a>
         ]. An antimicrobial susceptibility assessment of 100 strains isolated from endemic areas in Peru demonstrated a 26 percent resistance to ciprofloxacin [
         <a href="#rid61">
          61
         </a>
         ]; therefore, for treatment of severe or persistent disease, we favor administering the combination regimen of
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         and ciprofloxacin [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Previously,
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         was a preferred agent for treating Oroya fever [
         <a href="#rid34">
          34,63,64
         </a>
         ]; we favor it as an alternative treatment choice [
         <a href="#rid65">
          65
         </a>
         ]. It has activity against
         <em>
          B. bacilliformis
         </em>
         as well as
         <em>
          Salmonella
         </em>
         , a common secondary infection [
         <a href="#rid63">
          63,66
         </a>
         ]. However, treatment failure with persistent
         <em>
          Bartonella
         </em>
         bacteremia and relapse after treatment has been described among patients treated with chloramphenicol [
         <a href="#rid34">
          34,67
         </a>
         ]. In addition, successful treatment of Oroya fever with chloramphenicol does not eliminate the risk for development of verruga peruana [
         <a href="#rid57">
          57
         </a>
         ]. If chloramphenicol is used, coadministration of another antibiotic (such as a beta-lactam agent) is warranted.
        </p>
        <p>
         For the treatment of uncomplicated Oroya fever in children and pregnant women, we favor amoxicillin-clavulanic acid; in severe cases, we favor treatment with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ].
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         and
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          chloramphenicol
         </a>
         should be avoided in pregnancy [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         may be administered for patients with severe neurologic complications to reduce cerebral edema. Blood transfusion may be warranted in cases of severe anemia [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef77298" href="/z/d/graphic/77298.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         With successful therapy, clinical response is generally observed promptly, including defervescence and resolution of hemolysis.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Verruga peruana
         </span>
         <span class="headingEndMark">
          —
         </span>
         We favor
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for the treatment of verruga peruana in adults, children, and pregnant women [
         <a href="#rid46">
          46,62
         </a>
         ]. Azithromycin has been shown to have clinical efficacy comparable to
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          Rifampin
         </a>
         is an acceptable alternative agent for treating verruga peruana [
         <a href="#rid34">
          34,64
         </a>
         ], although its use as monotherapy may lead to rapid development of resistance, and treatment failures with rifampin have been described [
         <a href="#rid70">
          70
         </a>
         ]. In addition, the verruga zone contains regions with a high incidence of tuberculosis, and rifampin monotherapy may lead to mycobacterial resistance. Intramuscular
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         and oral rifampin have comparable efficacy; rifampin is favored over streptomycin, given the difficulty with adherence to intramuscular therapy [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          Ciprofloxacin
         </a>
         is also an acceptable alternative agent for treating verruga peruana [
         <a href="#rid46">
          46,57
         </a>
         ]. Its efficacy appears to be similar to that of
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , although there is less clinical experience with this agent, and it is not appropriate for the treatment of pregnant women.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9241" href="/z/d/drug information/9241.html" rel="external">
          Chloramphenicol
         </a>
         is not effective for the treatment of verruga peruana.
        </p>
        <p>
         Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef77298" href="/z/d/graphic/77298.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         With successful therapy, the skin lesions typically resolve within one month with no residual scarring.
        </p>
        <p>
         There is no available vaccine against
         <em>
          B. bacilliformis
         </em>
         . In vitro studies and whole-genomic sequencing of different strains have led to the synthesis of proteins that can serve as a potential target for vaccine development [
         <a href="#rid71">
          71-74
         </a>
         ]. A vaccine candidate that used an external membrane protein was evaluated in a murine model and shown to stimulate an immunogenic response with production of antibodies that inhibited the invasion of
         <em>
          B. bacilliformis
         </em>
         in human erythrocytes [
         <a href="#rid75">
          75
         </a>
         ]. Further studies are needed to characterize its immunogenic properties and elucidate the potential role of vaccines in preventing Carrion's disease.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         South American bartonellosis, or Carrion's disease, is an infection caused by
         <em>
          Bartonella bacilliformis
         </em>
         and transmitted by phlebotomine sand flies. The classic biphasic illness is characterized by an initial febrile phase, known as Oroya fever, followed by a secondary phase characterized by the development of skin lesions, known as verruga peruana. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         South American bartonellosis is endemic to the "verruga zone," a region in the Andes Mountains of Peru, Columbia, and Ecuador. New endemic areas have been described in these countries and can be related with new potential vectors. Oroya fever occurs most frequently among tourists and transient workers who are immunologically naïve to
         <em>
          B. bacilliformis
         </em>
         , while verruga peruana occurs most frequently among individuals native to the verruga zone. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The acute, or hematic, phase generally begins on average two months after inoculation, usually with insidious onset of mild fever, headache, anorexia, and malaise. This stage lasts between two to four weeks; mortality is low in patients who receive appropriate antimicrobial therapy. Anemia develops due to parasitic infection of red blood cells and cells of the reticuloendothelial system, with subsequent clearance of parasitized cells from the circulation. (See
         <a class="local">
          'Acute phase (Oroya fever)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The eruptive, or verruga, phase occurs after organisms invade capillary endothelial cells and induce cellular proliferation, producing hemangioma-like nodules in the skin and mucous membranes. Verruga peruana can appear weeks or months after the patient has apparently recovered from Oroya fever. However, most patients with verruga peruana do not have a clear antecedent history of febrile illness. (See
         <a class="local">
          'Eruptive phase (verruga peruana)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of Oroya fever is made by blood culture or by identification of
         <em>
          B. bacilliformis
         </em>
         organisms on a Giemsa-stained blood smear. The diagnosis of verruga peruana is generally based on characteristic clinical features and serology and confirmed by histopathologic analysis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         for treating uncomplicated Oroya fever in nonpregnant adults (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); for the treatment of severe or persistent disease, we favor the administration of ciprofloxacin in combination with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         . For the treatment of uncomplicated Oroya fever in children and pregnant women, we favor treatment with amoxicillin-clavulanic acid; in severe cases, we favor treatment with ceftriaxone. Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef77298" href="/z/d/graphic/77298.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Oroya fever'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for treating verruga peruana in adults, pregnant women, and children (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         );
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         and
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         are alternative choices. Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef77298" href="/z/d/graphic/77298.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Verruga peruana'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Maguina VC, Ugarte-Gil C, Brena CP, et al. Update of Carrion's disease. Rev Med Hered 2008; 19:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minnick MF, Anderson BE, Lima A, et al. Oroya fever and verruga peruana: bartonelloses unique to South America. PLoS Negl Trop Dis 2014; 8:e2919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander B. A review of bartonellosis in Ecuador and Colombia. Am J Trop Med Hyg 1995; 52:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schultz MG. A history of bartonellosis (Carrión's disease). Am J Trop Med Hyg 1968; 17:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laval RE. Daniel Alcides Carrion. Rev Chilena Infectol 2003; 20:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lydy SL, Lascano MS, Garcia-Perez JE, et al. Seroprevalence and risk factors for infection with Bartonella bacilliformis in Loja province, Ecuador. Emerg Microbes Infect 2018; 7:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urrutia LC, Patiño-Barbosa AM, Arroyave-Valencia F, et al. Oroya Fever, Verruga Peruana, and Other Bartonelloses Incidence Rates in Colombia (2009-2013). Cureus 2018; 10:e3528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez Clemente N, Ugarte-Gil CA, Solórzano N, et al. Bartonella bacilliformis: a systematic review of the literature to guide the research agenda for elimination. PLoS Negl Trop Dis 2012; 6:e1819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlin J, Laughlin LW, Romero S, et al. Epidemiology of endemic Bartonella bacilliformis: a prospective cohort study in a Peruvian mountain valley community. J Infect Dis 2002; 186:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andre R, Korves C, Fernandez R, et al. Host feeding behavior of Lutzomyia verrucarum in and around the house of bartonellosis patients in Perú. Am J Trop Med Hyg 1998; 59:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caceres AG. [Geographic distribution of Lutzomyia verrucarum (Townsend, 1913) (Diptera, Psychodidae, Phlebotominae), vector of human bartonellosis in Peru]. Rev Inst Med Trop Sao Paulo 1993; 35:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caceres AG, Galati EA, Le Pont F, Velasquez C. Possible role of Lutzomyia maranonensis and Lutzomyia robusta (Diptera: Psychodidae) as vectors of human bartonellosis in three provinces of region nor Oriental del Marañon, Peru. Rev Inst Med Trop Sao Paulo 1997; 39:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis BA, Rotz LD, Leake JA, et al. An outbreak of acute bartonellosis (Oroya fever) in the Urubamba region of Peru, 1998. Am J Trop Med Hyg 1999; 61:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Valle-Mendoza J, Rojas-Jaimes J, Vásquez-Achaya F, et al. Molecular identification of Bartonella bacilliformis in ticks collected from two species of wild mammals in Madre de Dios: Peru. BMC Res Notes 2018; 11:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amano Y, Rumbea J, Knobloch J, et al. Bartonellosis in Ecuador: serosurvey and current status of cutaneous verrucous disease. Am J Trop Med Hyg 1997; 57:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuya XL, Escalante-Kanashiro R, Tinco C, et al. Possible vertical transmission of Bartonella bacilliformis in Peru. Am J Trop Med Hyg 2015; 92:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huarcaya-Castilla E, Chinga-Alayo E, Chavez-Paz J, et al. Influence of El Niño Phenomenon in the epidemiology of human bartonellosis in the Departments of Ancash and Cusco between 1996 and 1999. Rev Med Hered 2004; 15:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinga-Alayo E, Huarcaya E, Nasarre C, et al. The influence of climate on the epidemiology of bartonellosis in Ancash, Peru. Trans R Soc Trop Med Hyg 2004; 98:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eremeeva ME, Gerns HL, Lydy SL, et al. Bacteremia, fever, and splenomegaly caused by a newly recognized bartonella species. N Engl J Med 2007; 356:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diniz PP, Morton BA, Tngrian M, et al. Infection of domestic dogs in peru by zoonotic bartonella species: a cross-sectional prevalence study of 219 asymptomatic dogs. PLoS Negl Trop Dis 2013; 7:e2393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caceres AG, Padilla Rojas CP, Arias Stella J, et al. Detection of Bartonella spp and Rickettsia spp in fleas, ticks, and lice collected in rural areas of Peru. Rev Peru Biol 2013; 20:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullins KE, Hang J, Jiang J, et al. Description of Bartonella ancashensis sp. nov., isolated from the blood of two patients with verruga peruana. Int J Syst Evol Microbiol 2015; 65:3339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hang J, Mullins KE, Clifford RJ, et al. Complete Genome Sequence of Bartonella ancashensis Strain 20.00, Isolated from the Blood of a Patient with Verruga Peruana. Genome Announc 2015; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullins KE, Hang J, Clifford RJ, et al. Whole-Genome Analysis of Bartonella ancashensis, a Novel Pathogen Causing Verruga Peruana, Rural Ancash Region, Peru. Emerg Infect Dis 2017; 23:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Quintanilla M, Dichter AA, Guerra H, Kempf VAJ. Carrion's disease: more than a neglected disease. Parasit Vectors 2019; 12:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrell DS, Falkow S. Frontal and stealth attack strategies in microbial pathogenesis. Nature 2004; 430:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harms A, Dehio C. Intruders below the radar: molecular pathogenesis of Bartonella spp. Clin Microbiol Rev 2012; 25:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huarcaya E, Best I, Rodriguez-Tafur J, et al. Cytokines and T-Lymphocute count in patients in the acute and chronic phases of Bartonella bacilliformis infection in an endemic area in peru: a pilot study. Rev Inst Med Trop Sao Paulo 2011; 53:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehio C, Lanz C, Pohl R, et al. Bartonella schoenbuchii sp. nov., isolated from the blood of wild roe deer. Int J Syst Evol Microbiol 2001; 51:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sander A, Zagrosek A, Bredt W, et al. Characterization of Bartonella clarridgeiae flagellin (FlaA) and detection of antiflagellin antibodies in patients with lymphadenopathy. J Clin Microbiol 2000; 38:2943.
          </a>
         </li>
         <li class="breakAll">
          Dehio C, Maguina C, Walker DH. Bartonelloses. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker D, Weller, P (Eds), Saunders Elsevier, Philadelphia 2011. p.265.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hicks LD, Minnick MF. Human vascular endothelial cells express epithelial growth factor in response to infection by Bartonella bacilliformis. PLoS Negl Trop Dis 2020; 14:e0008236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carrión's disease) in the modern era. Clin Infect Dis 2001; 33:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosek M, Lavarello R, Gilman RH, et al. Natural history of infection with Bartonella bacilliformis in a nonendemic population. J Infect Dis 2000; 182:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ihler GM. Bartonella bacilliformis: dangerous pathogen slowly emerging from deep background. FEMS Microbiol Lett 1996; 144:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montoya M, Maguina C, Vigo B, et al. Brote epidemico de enfermedad de Carrion en el Valle Sagrado de los Incas (Cuzco). Bol Soc Peru Med Int 1998; 11:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breña CJ, Maguiña VC, Hernandez DH, et al. Bartonelosis aguda en niños: Estudio de 32 casos en el Instituto Especializado de Salud del Niño y el Hospital Nacional Cayetano Heredia (Período 1993-2003). Rev Med Hered 2006; 17:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguiña VC, Peña CR, Ponce AM, et al. Manifestaciones clínicas y complicaciones de la fase aguda de bartonelosis o Fiebre de la Oroya en pacientes atendidos en el Hospital Nacional Cayetano Heredia. Rev Med Hered 2008; 19:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huerta A, Salas M, Yarinsueca J, Maguiña C. [Carrión's disease complicated with severe acute leptospirosis: a case report]. Rev Peru Med Exp Salud Publica 2014; 31:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-de-Guimaraes D, Menacho-Lopez J, Norabuena-Penadillo R, et al. Purpura trombocitopénica y bartonelosis aguda (enfermedad de Carrión) en Huaraz, Peru. Acta Med Peru 2006; 23:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguina VC, Ordaya EE, Ugarte-Gil C, et al. Compromiso cardiovascular en la fase aguda de la enfermedad de Carrión o bartonelosis humana: 20 años de experiencia en Hospital Nacional Cayetano Heredia. Acta Med Peru 2008; 25:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peñafiel-Sam J, Alarcón-Guevara S, Chang-Cabanillas S, et al. Infective endocarditis due to Bartonella bacilliformis associated with systemic vasculitis: a case report. Rev Soc Bras Med Trop 2017; 50:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           RICKETTS WE. Clinical manifestations of Carrión's disease. Arch Intern Med (Chic) 1949; 84:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguina C, Cok J, Gilman R, et al. Estudio prospectivo de la verruga peruana recurrente. Dermatol Peru 2003; 13:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguiña C, Gotuzzo E. Bartonellosis. New and old. Infect Dis Clin North Am 2000; 14:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornejo A, Gomes C, Suarez L, et al. An unidentified cluster of infection in the Peruvian Amazon region. J Infect Dev Ctries 2015; 9:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlin J, Laughlin L, Gordon S, et al. Serodiagnosis of Bartonella bacilliformis infection by indirect fluorescence antibody assay: test development and application to a population in an area of bartonellosis endemicity. J Clin Microbiol 2000; 38:4269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arias-Stella J, Lieberman PH, Erlandson RA, Arias-Stella J Jr. Histology, immunohistochemistry, and ultrastructure of the verruga in Carrion's disease. Am J Surg Pathol 1986; 10:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhutto AM, Nonaka S, Hashiguchi Y, Gomez EA. Histopathological and electron microscopical features of skin lesions in a patient with bartonellosis (verruga peruana). J Dermatol 1994; 21:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knobloch J, Solano L, Alvarez O, Delgado E. Antibodies to Bartonella bacilliformis as determined by fluorescence antibody test, indirect haemagglutination and ELISA. Trop Med Parasitol 1985; 36:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mallqui V, Speelmon EC, Verástegui M, et al. Sonicated diagnostic immunoblot for bartonellosis. Clin Diagn Lab Immunol 2000; 7:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Valle Mendoza J, Silva Caso W, Tinco Valdez C, et al. Diagnosis of Carrion's disease by direct blood PCR in thin blood smear negative samples. PLoS One 2014; 9:e92283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomes C, Martinez-Puchol S, Pons MJ, et al. Evaluation of PCR Approaches for Detection of Bartonella bacilliformis in Blood Samples. PLoS Negl Trop Dis 2016; 10:e0004529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguina C, Romero I, Soto N, et al. Historia natural de la fase eruptiva de la Verruga Peruana y la importancia de la prueba de western blot, reporte preliminar. F Dermatol 2002; 13:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angkasekwinai N, Atkins EH, Johnson RN, et al. Rapid and sensitive detection of Bartonella bacilliformis in experimentally infected sand flies by loop-mediated isothermal amplification (LAMP) of the Pap31 gene. PLoS Negl Trop Dis 2014; 8:e3342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angelakis E, Biswas S, Taylor C, et al. Heterogeneity of susceptibility to fluoroquinolones in Bartonella isolates from Australia reveals a natural mutation in gyrA. J Antimicrob Chemother 2008; 61:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Valle LJ, Flores L, Vargas M, et al. Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones. Int J Infect Dis 2010; 14:e506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinoza-Culupu A, Quispe-Gaspar R, Jaramillo M. Molecular characterization of quinolones resistance determining region (QRDR) of Bartonella bacilliformis topoisomerasa IV in clinical isolates. Rev Peru Biol 2014; 21:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza-Mujica G, Flores-León D. [Antimicrobial resistance of Bartonella bacilliformis strains from regions endemic to bartonellosis in Peru]. Rev Peru Med Exp Salud Publica 2015; 32:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarazona A, Maguina C, Lopez de Guimaraes, et al. Terapia antibiótica para el manejo de la Bartonellosis o enfermedad de Carrión en el Perú. Rev Peru Med Exp Salud Publica 2006; 23:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           URTEAGA O, PAYNE EH. Treatment of the acute febrile phase of Carrión's disease with chloramphenicol. Am J Trop Med Hyg 1955; 4:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arroyo A. Treatment outlines for non-complicated Carrion's disease in Caraz, Peru. Anales de la Facultad de Medecina 2008; 69:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gray GC, Johnson AA, Thornton SA, et al. An epidemic of Oroya fever in the Peruvian Andes. Am J Trop Med Hyg 1990; 42:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CUADRA M. Salmonellosis complication in human bartonellosis. Tex Rep Biol Med 1956; 14:97.
          </a>
         </li>
         <li class="breakAll">
          Pachas P, Rojas Y, Solorzano N, et al. Persistance of bacteremia by Bartonella bacilliformis post treatment with chloramphenicol. Abstract presented at the ASTHM 55th Annual Meeting, 2006, Atlanta, Georgia, USA.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amstey MS. Chloramphenicol therapy in pregnancy. Clin Infect Dis 2000; 30:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HODGSON CH. The treatment of Carrion's disease with large transfusions. Am J Trop Med Hyg 1947; 27:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maguina Vargas C. Bartonellosis o enfermedad de carrion. Nuevos aspectos de una vieja enfermedad. AFA Editores Importadores, Lima, Peru 1998; :7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dichter AA, Schultze TG, Becker SA, et al. Complete Genome Sequence of Bartonella bacilliformis Strain KC584 (ATCC 35686). Microbiol Resour Announc 2020; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarazona D, Padilla C, Cáceres O, et al. Whole Genome Sequencing and Comparative Analysis of Bartonella bacilliformis Strain INS, the Causative Agent of Carrion's Disease. Genome Announc 2013; 1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillen Y, Casadellà M, García-de-la-Guarda R, et al. Whole-Genome Sequencing of Two Bartonella bacilliformis Strains. Genome Announc 2016; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriquez-Camacho C, Ventosilla P, Minnick MF, et al. Proteins of Bartonella bacilliformis: Candidates for Vaccine Development. Int J Pept 2015; 2015:702784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas CPP, Pari PNL, Solis LS, et al. [DESIGN AND EVALUATION OF A MULTIEPITOPIC PROTEIN AS A CANDIDATE FOR A CARRION DISEASE VACCINE]. Rev Peru Med Exp Salud Publica 2019; 36:414.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5516 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Update of Carrion's disease
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25032975" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Oroya fever and verruga peruana: bartonelloses unique to South America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741177" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A review of bartonellosis in Ecuador and Colombia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4876803" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A history of bartonellosis (Carrión's disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Daniel Alcides Carrion
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29941982" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Seroprevalence and risk factors for infection with Bartonella bacilliformis in Loja province, Ecuador.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30648063" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oroya Fever, Verruga Peruana, and Other Bartonelloses Incidence Rates in Colombia (2009-2013).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23145188" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bartonella bacilliformis: a systematic review of the literature to guide the research agenda for elimination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12232839" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Epidemiology of endemic Bartonella bacilliformis: a prospective cohort study in a Peruvian mountain valley community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Host feeding behavior of Lutzomyia verrucarum in and around the house of bartonellosis patients in Perú
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7997750" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : [Geographic distribution of Lutzomyia verrucarum (Townsend, 1913) (Diptera, Psychodidae, Phlebotominae), vector of human bartonellosis in Peru].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9394538" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Possible role of Lutzomyia maranonensis and Lutzomyia robusta (Diptera: Psychodidae) as vectors of human bartonellosis in three provinces of region nor Oriental del Marañon, Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10463692" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : An outbreak of acute bartonellosis (Oroya fever) in the Urubamba region of Peru, 1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29941013" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Molecular identification of Bartonella bacilliformis in ticks collected from two species of wild mammals in Madre de Dios: Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9288812" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bartonellosis in Ecuador: serosurvey and current status of cutaneous verrucous disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25371184" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Possible vertical transmission of Bartonella bacilliformis in Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Influence of El Niño Phenomenon in the epidemiology of human bartonellosis in the Departments of Ancash and Cusco between 1996 and 1999
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14964812" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The influence of climate on the epidemiology of bartonellosis in Ancash, Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554119" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Bacteremia, fever, and splenomegaly caused by a newly recognized bartonella species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24040427" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Infection of domestic dogs in peru by zoonotic bartonella species: a cross-sectional prevalence study of 219 asymptomatic dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Detection of Bartonella spp and Rickettsia spp in fleas, ticks, and lice collected in rural areas of Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26296673" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Description of Bartonella ancashensis sp. nov., isolated from the blood of two patients with verruga peruana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26543106" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Complete Genome Sequence of Bartonella ancashensis Strain 20.00, Isolated from the Blood of a Patient with Verruga Peruana.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28221130" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Whole-Genome Analysis of Bartonella ancashensis, a Novel Pathogen Causing Verruga Peruana, Rural Ancash Region, Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30909982" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Carrion's disease: more than a neglected disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15241423" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Frontal and stealth attack strategies in microbial pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22232371" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Intruders below the radar: molecular pathogenesis of Bartonella spp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21755237" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cytokines and T-Lymphocute count in patients in the acute and chronic phases of Bartonella bacilliformis infection in an endemic area in peru: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11491358" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bartonella schoenbuchii sp. nov., isolated from the blood of wild roe deer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10921956" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Characterization of Bartonella clarridgeiae flagellin (FlaA) and detection of antiflagellin antibodies in patients with lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10921956" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Characterization of Bartonella clarridgeiae flagellin (FlaA) and detection of antiflagellin antibodies in patients with lymphadenopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32302357" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Human vascular endothelial cells express epithelial growth factor in response to infection by Bartonella bacilliformis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041596" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The expanding spectrum of Bartonella infections: II. Cat-scratch disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11512081" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Bartonellosis (Carrión's disease) in the modern era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10950782" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Natural history of infection with Bartonella bacilliformis in a nonendemic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8870245" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bartonella bacilliformis: dangerous pathogen slowly emerging from deep background.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Brote epidemico de enfermedad de Carrion en el Valle Sagrado de los Incas (Cuzco).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bartonelosis aguda en niños: Estudio de 32 casos en el Instituto Especializado de Salud del Niño y el Hospital Nacional Cayetano Heredia (Período 1993-2003).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Manifestaciones clínicas y complicaciones de la fase aguda de bartonelosis o Fiebre de la Oroya en pacientes atendidos en el Hospital Nacional Cayetano Heredia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25123883" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : [Carrión's disease complicated with severe acute leptospirosis: a case report].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Purpura trombocitopénica y bartonelosis aguda (enfermedad de Carrión) en Huaraz, Peru
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Compromiso cardiovascular en la fase aguda de la enfermedad de Carrión o bartonelosis humana: 20 años de experiencia en Hospital Nacional Cayetano Heredia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29160523" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Infective endocarditis due to Bartonella bacilliformis associated with systemic vasculitis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15393033" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical manifestations of Carrión's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Estudio prospectivo de la verruga peruana recurrente
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10738670" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bartonellosis. New and old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25989173" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : An unidentified cluster of infection in the Peruvian Amazon region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11060108" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Serodiagnosis of Bartonella bacilliformis infection by indirect fluorescence antibody assay: test development and application to a population in an area of bartonellosis endemicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2428261" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Histology, immunohistochemistry, and ultrastructure of the verruga in Carrion's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8014271" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Histopathological and electron microscopical features of skin lesions in a patient with bartonellosis (verruga peruana).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3911360" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Antibodies to Bartonella bacilliformis as determined by fluorescence antibody test, indirect haemagglutination and ELISA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10618267" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Sonicated diagnostic immunoblot for bartonellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24651298" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Diagnosis of Carrion's disease by direct blood PCR in thin blood smear negative samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26959642" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Evaluation of PCR Approaches for Detection of Bartonella bacilliformis in Blood Samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Historia natural de la fase eruptiva de la Verruga Peruana y la importancia de la prueba de western blot, reporte preliminar
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25522230" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Rapid and sensitive detection of Bartonella bacilliformis in experimentally infected sand flies by loop-mediated isothermal amplification (LAMP) of the Pap31 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155180" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Recommendations for treatment of human infections caused by Bartonella species.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334491" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Heterogeneity of susceptibility to fluoroquinolones in Bartonella isolates from Australia reveals a natural mutation in gyrA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19969497" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Molecular characterization of quinolones resistance determining region (QRDR) of Bartonella bacilliformis topoisomerasa IV in clinical isolates
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26732912" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : [Antimicrobial resistance of Bartonella bacilliformis strains from regions endemic to bartonellosis in Peru].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Terapia antibiótica para el manejo de la Bartonellosis o enfermedad de Carrión en el Perú
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14376776" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of the acute febrile phase of Carrión's disease with chloramphenicol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Treatment outlines for non-complicated Carrion's disease in Caraz, Peru
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2316791" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : An epidemic of Oroya fever in the Peruvian Andes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13337733" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Salmonellosis complication in human bartonellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13337733" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Salmonellosis complication in human bartonellosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10619781" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Chloramphenicol therapy in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20284814" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The treatment of Carrion's disease with large transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bartonellosis o enfermedad de carrion. Nuevos aspectos de una vieja enfermedad
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31896649" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Complete Genome Sequence of Bartonella bacilliformis Strain KC584 (ATCC 35686).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23409255" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Whole Genome Sequencing and Comparative Analysis of Bartonella bacilliformis Strain INS, the Causative Agent of Carrion's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27389274" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Whole-Genome Sequencing of Two Bartonella bacilliformis Strains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26413097" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Proteins of Bartonella bacilliformis: Candidates for Vaccine Development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31800933" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : [DESIGN AND EVALUATION OF A MULTIEPITOPIC PROTEIN AS A CANDIDATE FOR A CARRION DISEASE VACCINE].
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
